Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21371585 | 0.88 | LMNA (0.31) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL6209009 | 0.83 | LMNA (0.50) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL6209012 | 0.83 | LMNA (0.50) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL13747070 | 0.83 | CA1 (0.31) | — | |
| SCHEMBL10245268 | 0.83 | LMNA (0.50) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL17543917 | 0.83 | — | — | |
| SCHEMBL14176493 | 0.81 | LMNA (0.31) | LMNATSHR | |
| SCHEMBL24191889 | 0.79 | — | — | |
| SCHEMBL10246313 | 0.79 | TAS1R3 (0.33) | — | |
| SCHEMBL15174715 | 0.79 | LMNA (0.31) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626772-A1 | USE OF A MELAMINE BASED COMPOUND AND A HALS COMPOUND AS HEAT STABILIZER IN POLYMERS | Borealis AG (AT) | 2020-03-25 | — | — | EP | disclosed |
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-8883378-B2 | Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-8637215-B2 | Colored curable composition, color filter and method of producing color filter, solid-state image sensor and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120289696-A1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2012-11-15 | — | — | US | disclosed |
| US-8242143-B2 | Thiazolyl mGluR5 antagonists and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110230526-A1 | Thiazolyl Mglur5 Antagonists and Methods for Their Use | MERCK SHARP & DOHME CORP. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110217636-A1 | COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2011-09-08 | — | — | US | disclosed |
| US-7879882-B2 | glutamate receptor antagonists such as 3-fluoro-5-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-2-yl]benzonitrile, used for the treatment of ischemia, , schizophrenia, obesity, attention deficit disorders, epilepsy, eating, cardiovacular, neurodegenerative, psychological and sleep disorders | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
| US-7511043-B2 | FXR modulators | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | ANGION BIOMEDICA CORPORATION (US) | 2008-03-06 | — | — | US | disclosed |
| US-20040176426-A1 | FXR modulators | TULARIK, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6777446-B2 | FARNESOID X RECEPTOR; TREATING DISEASES ASSOCIATED WITH ABNORMALLY HIGH OR LOW CHOLESTEROL LEVELS. | TULARIK, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | TULARIK INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002020463-A2 | FXR MODULATORS | TULARIK INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289696-A1 | THIAZOLYL MGLUR5 ANTAGONISTS AND METHODS FOR THEIR USE | GRM5, GRIK5, GRM3 | LMNA 4658/4885CNR1 117/4885ADRA1A 1135/4885 |
| US-20020120137-A1 | Farnesoid X receptor; treating diseases associated with abnormally high or low cholesterol levels. | NR1H4, NR1H2, NR1H3 | LMNA 4130/4885CNR1 1039/4885ADRA1A 456/4885 |
| US-10314816-B2 | Antimicrobial compounds, compositions and methods of use thereof | CLPP, ATP5ME, PCNA | LMNA 2044/4885CNR1 4123/4885ADRA1A 3670/4885 |
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | GRM5, GRIK5, GRM3 | LMNA 4658/4885CNR1 117/4885ADRA1A 1135/4885 |
| US-20040176426-A1 | FXR modulators | NR1H4, CYP7A1, CYP7B1 | LMNA 4473/4885CNR1 1314/4885ADRA1A 408/4885 |
| US-20110230526-A1 | Thiazolyl Mglur5 Antagonists and Methods for Their Use | GRM5, GRIK5, GRM3 | LMNA 4658/4885CNR1 117/4885ADRA1A 1135/4885 |
| US-20080058312-A1 | Modulators of hepatocyte growth factor/c-Met activity | HGF, MET, HDGF | LMNA 4652/4885CNR1 2550/4885ADRA1A 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.